Intersect ENT Company Profile (NASDAQ:XENT)

About Intersect ENT (NASDAQ:XENT)

Intersect ENT logoIntersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company's commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment, Supplies & Distribution
  • Sub-Industry: N/A
  • Symbol: NASDAQ:XENT
  • CUSIP: N/A
  • Web:
  • Market Cap: $893.18 million
  • Outstanding Shares: 29,189,000
Average Prices:
  • 50 Day Moving Avg: $30.07
  • 200 Day Moving Avg: $26.45
  • 52 Week Range: $7.65 - $33.25
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -78.46
  • P/E Growth: -2.35
Sales & Book Value:
  • Annual Revenue: $87.16 million
  • Price / Sales: 10.25
  • Book Value: $3.88 per share
  • Price / Book: 7.89
  • EBITDA: ($19,710,000.00)
  • Net Margins: -22.94%
  • Return on Equity: -17.60%
  • Return on Assets: -15.64%
  • Current Ratio: 9.81%
  • Quick Ratio: 9.17%
  • Average Volume: 266,775 shs.
  • Beta: 0.72
  • Short Ratio: 2.34

Frequently Asked Questions for Intersect ENT (NASDAQ:XENT)

What is Intersect ENT's stock symbol?

Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."

How were Intersect ENT's earnings last quarter?

Intersect ENT, Inc. (NASDAQ:XENT) issued its quarterly earnings results on Tuesday, August, 1st. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.11. The company had revenue of $24 million for the quarter, compared to analyst estimates of $22.62 million. Intersect ENT had a negative return on equity of 17.60% and a negative net margin of 22.94%. The company's quarterly revenue was up 24.4% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.21) earnings per share. View Intersect ENT's Earnings History.

When will Intersect ENT make its next earnings announcement?

Intersect ENT is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Intersect ENT.

Where is Intersect ENT's stock going? Where will Intersect ENT's stock price be in 2017?

10 analysts have issued 12-month target prices for Intersect ENT's shares. Their predictions range from $14.00 to $40.00. On average, they anticipate Intersect ENT's stock price to reach $27.11 in the next year. View Analyst Ratings for Intersect ENT.

What are analysts saying about Intersect ENT stock?

Here are some recent quotes from research analysts about Intersect ENT stock:

  • 1. According to Zacks Investment Research, "Intersect ENT, Inc. is a commercial drug-device company. The Company's initial products, PROPEL and PROPEL mini, are drug-eluting implants for use in patients with chronic sinusitis. It offers products and therapies for ear, nose, and throat surgeons to improve treatment for their patients with chronic diseases. Intersect ENT, Inc. is headquartered in Menlo Park, California. " (10/5/2017)
  • 2. Northland Securities analysts commented, "We remain bullish on the takeout potential of this story. Key Points As a reminder, RESOLVE would be in an office" setting, hence would not be subject to the facility payment pressures currently being witnessed by PROPEL on the Medicare front. It is our understanding that the company would advocate the use of an unlisted J-code (physician administered drug) immediately after NDA approval." (3/13/2017)

Who are some of Intersect ENT's key competitors?

Who are Intersect ENT's key executives?

Intersect ENT's management team includes the folowing people:

  • Lisa D. Earnhardt, President, Chief Executive Officer, Director
  • Jeryl L. Hilleman, Chief Financial Officer
  • Richard E. Kaufman, Senior Vice President, Chief Operating Officer
  • David A. Lehman, General Counsel
  • Gwen Carscadden, Chief People Officer
  • Kieran T. Gallahue, Lead Director
  • Teresa L. Kline, Director
  • William Anthony Vernon, Director
  • Cynthia L. Lucchese, Independent Director
  • Dana G. Mead Jr., Independent Director

Who owns Intersect ENT stock?

Intersect ENT's stock is owned by many different of retail and institutional investors. Top institutional investors include Mutual of America Capital Management LLC (0.31%). Company insiders that own Intersect ENT stock include Amy Wolbeck, Frederic H Moll, James Stambaugh, Jeryl L Hilleman, Kieran Gallahue, Lisa D Earnhardt and Richard E Kaufman. View Institutional Ownership Trends for Intersect ENT.

Who sold Intersect ENT stock? Who is selling Intersect ENT stock?

Intersect ENT's stock was sold by a variety of institutional investors in the last quarter, including Mutual of America Capital Management LLC. Company insiders that have sold Intersect ENT stock in the last year include Jeryl L Hilleman, Lisa D Earnhardt and Richard E Kaufman. View Insider Buying and Selling for Intersect ENT.

How do I buy Intersect ENT stock?

Shares of Intersect ENT can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intersect ENT's stock price today?

One share of Intersect ENT stock can currently be purchased for approximately $30.60.

MarketBeat Community Rating for Intersect ENT (NASDAQ XENT)
Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  232 (Vote Outperform)
Underperform Votes:  93 (Vote Underperform)
Total Votes:  325
MarketBeat's community ratings are surveys of what our community members think about Intersect ENT and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Intersect ENT (NASDAQ:XENT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 8 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $27.11 (11.40% downside)
Consensus Price Target History for Intersect ENT (NASDAQ:XENT)
Price Target History for Intersect ENT (NASDAQ:XENT)
Analysts' Ratings History for Intersect ENT (NASDAQ:XENT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/13/2017Canaccord GenuityBoost Price TargetBuy$32.00 -> $37.00LowView Rating Details
9/11/2017Bank of America CorporationBoost Price TargetBuy$33.00 -> $40.00HighView Rating Details
8/22/2017Piper Jaffray CompaniesReiterated RatingBuy$35.00LowView Rating Details
8/2/2017Deutsche Bank AGSet Price TargetBuy$27.00 -> $31.00HighView Rating Details
8/2/2017Northland SecuritiesReiterated RatingHold$25.00HighView Rating Details
5/10/2017William BlairReiterated RatingOutperformLowView Rating Details
5/3/2017WedbushBoost Price TargetOutperform -> Outperform$25.00 -> $26.00HighView Rating Details
12/6/2016GuggenheimInitiated CoverageBuy$20.00N/AView Rating Details
11/4/2016Leerink SwannReiterated RatingOutperform$21.00 -> $14.00N/AView Rating Details
11/2/2016J P Morgan Chase & CoDowngradeOverweight -> Neutral$25.00 -> $16.00N/AView Rating Details
8/4/2016BTIG ResearchReiterated RatingHold$14.00N/AView Rating Details
3/24/2016Cantor FitzgeraldReiterated RatingBuy$29.00N/AView Rating Details
(Data available from 10/20/2015 forward)


Earnings History for Intersect ENT (NASDAQ:XENT)
Earnings by Quarter for Intersect ENT (NASDAQ:XENT)
Earnings History by Quarter for Intersect ENT (NASDAQ XENT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2017($0.20)N/AView Earnings Details
8/1/2017Q2 2017($0.19)($0.08)$22.62 million$24.00 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.25)($0.23)$19.39 million$20.47 millionViewListenView Earnings Details
2/28/2017Q416($0.20)($0.17)$23.47 million$24.20 millionViewListenView Earnings Details
11/2/2016Q316($0.27)($0.22)$17.80 million$18.50 millionViewN/AView Earnings Details
8/2/2016Q216($0.26)($0.21)$18.91 million$19.30 millionViewN/AView Earnings Details
5/5/2016Q116($0.29)($0.29)$16.92 million$16.69 millionViewN/AView Earnings Details
2/23/2016Q415($0.25)($0.20)$18.36 million$18.80 millionViewListenView Earnings Details
11/4/2015Q315($0.29)($0.35)$14.80 million$14.20 millionViewN/AView Earnings Details
8/5/2015Q215($0.26)($0.23)$14.74 million$15.20 millionViewN/AView Earnings Details
5/6/2015Q115($0.33)($0.23)$13.00 million$13.37 millionViewN/AView Earnings Details
2/26/2015Q414($0.29)($0.16)$12.20 million$13.40 millionViewN/AView Earnings Details
11/5/2014Q314($0.35)($0.32)$8.20 million$9.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Intersect ENT (NASDAQ:XENT)
2017 EPS Consensus Estimate: ($0.77)
2018 EPS Consensus Estimate: ($0.46)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.26)($0.22)($0.24)
Q2 20173($0.19)($0.19)($0.19)
Q3 20173($0.26)($0.17)($0.21)
Q4 20173($0.17)($0.06)($0.13)
Q1 20182($0.16)($0.08)($0.12)
Q2 20182($0.12)($0.11)($0.12)
Q3 20182($0.14)($0.11)($0.13)
Q4 20182($0.14)($0.06)($0.10)
(Data provided by Zacks Investment Research)


Dividend History for Intersect ENT (NASDAQ:XENT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Intersect ENT (NASDAQ:XENT)
Insider Ownership Percentage: 13.70%
Institutional Ownership Percentage: 83.12%
Insider Trades by Quarter for Intersect ENT (NASDAQ:XENT)
Institutional Ownership by Quarter for Intersect ENT (NASDAQ:XENT)
Insider Trades by Quarter for Intersect ENT (NASDAQ:XENT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/16/2017Lisa D EarnhardtInsiderSell20,000$28.37$567,400.00View SEC Filing  
10/4/2017Jeryl L HillemanCFOSell12,833$29.96$384,476.68View SEC Filing  
9/25/2017Richard E KaufmanCOOSell13,639$28.97$395,121.83View SEC Filing  
9/15/2017Lisa D EarnhardtInsiderSell20,000$30.19$603,800.00View SEC Filing  
9/5/2017Jeryl L HillemanCFOSell12,833$31.05$398,464.65View SEC Filing  
8/28/2017Richard E KaufmanCOOSell22,425$30.22$677,683.50View SEC Filing  
8/15/2017Lisa D EarnhardtInsiderSell20,000$30.79$615,800.00View SEC Filing  
8/4/2017Jeryl L HillemanCFOSell12,833$29.00$372,157.00View SEC Filing  
7/25/2017Richard E KaufmanCOOSell12,500$28.25$353,125.00View SEC Filing  
7/17/2017Lisa D EarnhardtInsiderSell20,000$29.03$580,600.00View SEC Filing  
7/10/2017Jeryl L HillemanCFOSell12,835$27.18$348,855.30View SEC Filing  
6/15/2017Lisa D EarnhardtInsiderSell20,000$26.10$522,000.00View SEC Filing  
5/22/2017Richard E KaufmanCOOSell20,000$22.87$457,400.00View SEC Filing  
5/15/2017Lisa D EarnhardtInsiderSell20,000$22.98$459,600.00View SEC Filing  
4/20/2017Richard E KaufmanCOOSell1,250$17.25$21,562.50View SEC Filing  
4/17/2017Lisa D EarnhardtInsiderSell20,000$16.06$321,200.00View SEC Filing  
3/15/2017Lisa D EarnhardtInsiderSell20,000$15.02$300,400.00View SEC Filing  
10/20/2016Richard E KaufmanCOOSell3,603$16.58$59,737.74View SEC Filing  
10/17/2016Lisa D EarnhardtInsiderSell400$18.00$7,200.00View SEC Filing  
9/7/2016Amy WolbeckVPSell28,664$15.83$453,751.12View SEC Filing  
9/6/2016James StambaughVPSell4,000$16.00$64,000.00View SEC Filing  
8/3/2016James StambaughVPSell3,977$17.00$67,609.00View SEC Filing  
7/18/2016James StambaughVPSell5,000$15.33$76,650.00View SEC Filing  
6/13/2016James StambaughVPSell500$14.38$7,190.00View SEC Filing  
5/16/2016Kieran GallahueDirectorBuy8,000$12.64$101,120.00View SEC Filing  
4/27/2016Amy WolbeckVPSell2,000$20.01$40,020.00View SEC Filing  
4/20/2016Richard E KaufmanCOOSell3,603$18.86$67,952.58View SEC Filing  
4/18/2016Lisa D EarnhardtCEOSell28,500$18.69$532,665.00View SEC Filing  
3/21/2016Richard E KaufmanCOOSell3,603$16.51$59,485.53View SEC Filing  
3/15/2016Lisa D EarnhardtCEOSell9,000$18.01$162,090.00View SEC Filing  
3/14/2016Frederic H MollDirectorSell1,299$18.53$24,070.47View SEC Filing  
3/8/2016Frederic H MollDirectorSell601$18.56$11,154.56View SEC Filing  
2/22/2016Richard E KaufmanCOOSell3,603$18.65$67,195.95View SEC Filing  
1/21/2016Richard E. KaufmanCOOSell7,206$17.93$129,203.58View SEC Filing  
1/15/2016Lisa D. EarnhardtCEOSell12,500$19.26$240,750.00View SEC Filing  
12/15/2015Lisa D EarnhardtCEOSell6,820$19.85$135,377.00View SEC Filing  
11/16/2015Lisa D EarnhardtCEOSell6,818$18.00$122,724.00View SEC Filing  
10/15/2015Lisa D EarnhardtCEOSell6,818$18.72$127,632.96View SEC Filing  
9/15/2015Lisa D EarnhardtCEOSell6,818$25.99$177,199.82View SEC Filing  
9/11/2015Frederic H MollDirectorSell10,000$25.21$252,100.00View SEC Filing  
8/17/2015Lisa D EarnhardtCEOSell6,818$28.51$194,381.18View SEC Filing  
7/20/2015James StambaughVPSell12,000$30.52$366,240.00View SEC Filing  
7/15/2015Lisa D EarnhardtCEOSell19,318$29.62$572,199.16View SEC Filing  
6/15/2015Lisa D EarnhardtCEOSell19,318$29.30$566,017.40View SEC Filing  
5/8/2015James StambaughVPSell2,785$23.87$66,477.95View SEC Filing  
4/13/2015Amy WolbeckVPSell16,000$26.25$420,000.00View SEC Filing  
4/1/2015James StambaughVPSell8,343$25.50$212,746.50View SEC Filing  
3/16/2015Lisa D EarnhardtInsiderSell19,318$23.56$455,132.08View SEC Filing  
3/11/2015Amy WolbeckVPSell8,000$23.06$184,480.00View SEC Filing  
3/9/2015James StambaughVPSell8,343$23.02$192,055.86View SEC Filing  
2/17/2015Lisa D EarnhardtInsiderSell19,318$22.69$438,325.42View SEC Filing  
2/12/2015Amy WolbeckVPSell8,000$22.12$176,960.00View SEC Filing  
2/2/2015James StambaughVPSell8,343$20.98$175,036.14View SEC Filing  
1/26/2015Robert H Binney JrVPSell6,300$21.18$133,434.00View SEC Filing  
9/11/2014Cynthia L LuccheseDirectorBuy5,000$17.11$85,550.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Intersect ENT (NASDAQ:XENT)
Latest Headlines for Intersect ENT (NASDAQ:XENT)
DateHeadline logoIntersect ENT, Inc. (XENT) Forecasted to Earn Q1 2018 Earnings of ($0.08) Per Share - October 18 at 11:28 AM logoCommit To Buy Intersect ENT At $25, Earn 16.6% Annualized Using Options - October 18 at 10:52 AM logoIntersect ENT, Inc. (XENT) Insider Lisa D. Earnhardt Sells 20,000 Shares - October 17 at 7:26 PM logoIntersect ENT, Inc. Forecasted to Earn Q2 2018 Earnings of ($0.11) Per Share (XENT) - October 17 at 11:46 AM logoIntersect ENT to Report Third Quarter 2017 Financial Results - October 17 at 9:24 AM logoOcular Therapeutix (OCUL) vs. Intersect ENT (XENT) Head-To-Head Comparison - October 14 at 12:36 PM logoETFs with exposure to Intersect ENT, Inc. : October 10, 2017 - October 11 at 9:43 AM logoETFs with exposure to Intersect ENT, Inc. : October 10, 2017 - October 11 at 9:43 AM logoThe Zacks Analyst Blog Highlights: IDEXX Laboratories, Steris, K2M Group Holdings, Tandem Diabetes Care and Intersect ENT - October 11 at 9:43 AM logoIntersect ENT, Inc. :XENT-US: Earnings Analysis: Q2, 2017 By the Numbers : October 9, 2017 - October 10 at 8:31 AM logoINTERSECT ENT INC - October 9 at 9:32 AM logoIntersect ENT Announces Presentation of Results from RESOLVE II, a Pivotal Phase III Study Evaluating the Safety and Efficacy of SINUVA™, an Investigational Steroid Releasing Sinus Implant - October 9 at 9:32 AM logoIntersect ENT, Inc. (XENT) Receives Average Rating of "Buy" from Analysts - October 7 at 2:52 AM logoIntersect ENT (XENT) and Its Competitors Financial Analysis - October 6 at 4:10 PM logoInsider Selling: Intersect ENT Inc (XENT) CFO Sells 12,833 Shares of Stock - October 5 at 7:26 PM logoThe Saga to Revoke Obamacare Continues: 3 MedTech Picks - Nasdaq - October 5 at 6:34 PM logoThe Saga to Revoke Obamacare Continues: 3 MedTech Picks - October 5 at 6:34 PM logoIntersect ENT, Inc. (XENT) Stock Rating Upgraded by Zacks Investment Research - October 5 at 9:50 AM logoIntersect ENT, Inc. (XENT) Expected to Announce Earnings of -$0.20 Per Share - October 2 at 8:32 AM logoInsider Selling: Intersect ENT, Inc. (XENT) COO Sells 13,639 Shares of Stock - September 27 at 7:46 PM logoIntersect ENT, Inc. breached its 50 day moving average in a Bearish Manner : XENT-US : September 21, 2017 - September 23 at 12:13 PM logoIntersect ENT, Inc. – Value Analysis (NASDAQ:XENT) : September 22, 2017 - September 23 at 12:13 PM logoCanaccord Genuity Reiterates "Buy" Rating for Intersect ENT, Inc. (XENT) - September 13 at 3:34 PM logoAnalysts Issue Forecasts for Intersect ENT, Inc.'s Q3 2017 Earnings (XENT) - September 13 at 7:42 AM logoIntersect ENT (XENT) Reports Presentation of a Meta-Analysis From Two Randomized Studies Evaluating the Safety ... - - September 12 at 12:30 PM logoIntersect ENT, Inc. (XENT) Receives Average Recommendation of "Buy" from Analysts - September 12 at 3:06 AM logoIntersect ENT, Inc. (XENT) Price Target Increased to $40.00 by Analysts at Bank of America Corporation - September 11 at 8:22 AM logoIntersect ENT Announces Presentation of a Meta-Analysis From Two Randomized Studies Evaluating the Safety and ... - Business Wire (press release) - September 10 at 9:59 AM logoIntersect ENT Announces Presentation of a Meta-Analysis From Two Randomized Studies Evaluating the Safety and Efficacy of SINUVA™, an Investigational Steroid Releasing Sinus Implant - September 10 at 9:59 AM logoJeryl L. Hilleman Sells 12,833 Shares of Intersect ENT, Inc. (XENT) Stock - September 6 at 8:26 PM logoIntersect ENT, Inc. (XENT) COO Sells $677,683.50 in Stock - August 29 at 7:18 PM logoIntersect ENT, Inc. (XENT) Earns Buy Rating from Piper Jaffray Companies - August 22 at 4:28 PM logoIntersect ENT, Inc. (XENT) Given Consensus Recommendation of "Buy" by Analysts - August 18 at 2:42 PM logoInsider Selling: Intersect ENT, Inc. (XENT) Insider Sells 20,000 Shares of Stock - August 17 at 7:38 PM logoETFs with exposure to Intersect ENT, Inc. : August 14, 2017 - August 15 at 8:31 AM logo-$0.20 Earnings Per Share Expected for Intersect ENT, Inc. (NASDAQ:XENT) This Quarter - August 7 at 6:26 PM logoFY2017 EPS Estimates for Intersect ENT, Inc. Raised by William Blair (NASDAQ:XENT) - August 4 at 10:00 AM logoIntersect ENT, Inc. Forecasted to Post Q3 2017 Earnings of ($0.26) Per Share (NASDAQ:XENT) - August 4 at 7:16 AM logoQ3 2017 EPS Estimates for Intersect ENT, Inc. Decreased by Analyst (XENT) - August 4 at 7:16 AM logoLeerink Swann Equities Analysts Lift Earnings Estimates for Intersect ENT, Inc. (NASDAQ:XENT) - August 3 at 4:40 PM logoIntersect ENT Reports Second Quarter 2017 Results - Business Wire (press release) - August 3 at 9:05 AM logoEdited Transcript of XENT earnings conference call or presentation 1-Aug-17 8:30pm GMT - August 3 at 9:05 AM logoIntersect ENT, Inc. (NASDAQ:XENT) Stock Rating Reaffirmed by Canaccord Genuity - August 2 at 4:38 PM logoIntersect ENT, Inc. (XENT) Stock Rating Reaffirmed by Northland Securities - August 2 at 2:02 PM logoInvestor Network: Intersect ENT Inc to Host Earnings Call - August 2 at 8:54 AM logoIntersect ENT Reports Second Quarter 2017 Results - August 2 at 8:54 AM logoIntersect ENT reports 2Q loss - August 2 at 8:54 AM logoIntersect ENT, Inc. (NASDAQ:XENT) Releases Quarterly Earnings Results, Beats Estimates By $0.11 EPS - August 1 at 10:46 PM logoETFs with exposure to Intersect ENT, Inc. : July 31, 2017 - August 1 at 8:01 AM logoIntersect Looks To Boost Position In ENT Implant Market, Driving Stock Up - July 29 at 8:51 AM



Intersect ENT (XENT) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.